Administration of SGLT2 inhibitor empagliflozin against TNF-α induced endothelial dysfunction in human venous and arterial endothelial cells

Volume: 120, Pages: 25 - 25
Published: Jul 1, 2018
Abstract
Background: Type 2 diabetes is commonly associated with vascular inflammation and endothelial dysfunction. Clinical trials have shown unexpected cardiovascular benefits of SGLT2 inhibitors (SGLT2i) in diabetic individuals. We recently showed that SGLT2i empagliflozin (Empa) directly affects the healthy heart by activating vasodilation and inhibiting sodium hydrogen exchanger 1 (NHE-1). Here, we studied if Empa offers protection against TNF-α...
Paper Details
Title
Administration of SGLT2 inhibitor empagliflozin against TNF-α induced endothelial dysfunction in human venous and arterial endothelial cells
Published Date
Jul 1, 2018
Volume
120
Pages
25 - 25
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.